CA
NZ
UK
AU
IND
US
The cash cushion and modest EPS beat together suggest the firm can press forward with its KRAS programs without immediate equity dilution.
Brookdale Senior Living's operational update reveals a significant 4.3% increase in adjusted EBITDA year-over-year, alongside a 5.5% rise in same-community revenue per available room (RevPAR). This positive development occurs despite an overall decline in total revenue, indicating that the company is strategically enhancing profitability …
Investors gain a clear efficacy signal that could translate into market‑share advantage if regulatory approval follows. The milestone also validates the company’s PLK1 inhibition strategy, reinforcing its therapeutic relevance in a high‑unmet‑need cancer segment.
Strong profit guidance from Cardinal Health has prompted analysts to lift their price targets for the healthcare provider. This upward revision reflects bullish sentiment surrounding the company after it shared news of increased profitability, despite some challenges during the quarter. The adjustment signifies a …
Organic revenue crept 0.1 %, the strongest pace since Q3 2023, while the non‑GAAP operating margin expanded 420 basis points to 20.5 %. Management highlighted a $100 million share repurchase at $174 average and a raised 2026 guidance that lifts the organic revenue outlook …
The cash decline coincided with anEarnings Per Shareof $‑0.45, falling short of the $‑0.37 consensus estimate.
The financial results coincided with a 428.8% year-to-date surge in share price, reflecting heightened investor confidence in the company’s innovative boron chemistry platform and therapeutic advancements. A recent EPS report shows a $-0.29 per share loss against a consensus estimate of $-0.23, underscoring the …
Apogee Therapeutics, Inc. (NASDAQ: APGE) secured shareholder approval for its merger with AbbVie after 46,526,253 votes represented 74.87% of the 62,140,183 shares entitled to vote at the August 11 special meeting. The outcome follows a modest quarterlyEarningsbeat and a share price hovering near its …
Bio-Techne Corporation (NASDAQ: TECH) reported an earnings per share (EPS) of $0.53 for the quarter ending March 31. This figure slightly beats analysts' expectations, which had set the consensus at $0.55. The positive deviation indicates strong operational performance within the life sciences sector, where …
Arbutus Biopharma Corporation (NASDAQ: ABUS) reported a significant $178 million financial uplift from its recent settlement with Moderna, Inc. This payment stems from a larger $950 million agreement overPatentinfringement related to lipid nanoparticle technology. The settlement not only alleviates a vital pressure point for …
Please wait processing your request...